HY07121 not checked
Sichuan Huiyu Pharmaceutical Co., Ltd · HY0007-101 · HY0007-SC-101
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HY07121 should be administered intravenously at recommended dose.”In the company’s words, NCT06639256 on ClinicalTrials.gov
- Tested for
- Safety (2 trials), Tolerability (2 trials), Efficacy (2 trials)
- Main trialPhase 1/2
- “This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.”In the company’s words, NCT06639256 on ClinicalTrials.gov
- Other names
- HY0007-101 · HY0007-SC-101
Coming up2
- 26 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 26 May 2027 | Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors | |
| Phase 1/2Not yet recruiting | Apr 2028 | Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026